SP was shown to be a mitogen in osteosarcoma cells, while an NK-1R antagonist, aprepitant, counteracts the effects of SP, via the inhibition of proliferation and induction of apoptosis of osteosarcoma tumor cells. Here, TACR1 is linked to osteosarcoma.